Literature DB >> 1704430

Identical IgM antibodies recognizing a glycine-alanine epitope are induced during acute infection with Epstein-Barr virus and cytomegalovirus.

G Rhodes1, R S Smith, R E Rubin, J Vaughan, C A Horwitz.   

Abstract

We studied antibody production in serial serum samples from patients with acute Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections. Sera were analyzed both by enzyme-linked immunosorbent assay (ELISA) using a synthetic peptide (P62) derived from the glycine-alanine repeating region of the Epstein-Barr nuclear antigen (EBNA-1) and by immunoblotting. In prior studies, we have shown that patients with acute EBV infection make IgM antibodies that react with this peptide, that recognize a viral-specific protein (EBNA-1), and that bind with a number of proteins present in uninfected cells; however, antibody binding to these autoantigens was inhibited by the peptide. IgG antibodies reactive with the peptide did not appear until months after the disease and were specific for the EBNA-1 protein. We now find that patients with acute CMV infection but not those with acute infections from a variety of other nonherpes organisms also produce IgM antibodies that recognize the EBV-derived peptide P62. These antibodies also appear to recognize the same cellular proteins as the EBV-induced IgM antibodies. The IgM antibodies appeared in all acutely infected CMV patients studied and occurred both in patients with previous EBV infections and in one patient studied who had not previously been exposed to EBV. It appears that infection with EBV or CMV can induce the synthesis of a very similar or identical set of IgM antibodies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1704430     DOI: 10.1002/jcla.1860040613

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  9 in total

1.  Real-time Epstein-Barr virus PCR for the diagnosis of primary EBV infections and EBV reactivation.

Authors:  Rianne Luderer; Marieke Kok; Hubert G M Niesters; Rob Schuurman; Okke de Weerdt; Steven F T Thijsen
Journal:  Mol Diagn       Date:  2005

Review 2.  Serological diagnosis of Epstein-Barr virus infection: Problems and solutions.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2012-02-12

3.  Epstein-Barr virus-induced autoimmune responses. I. Immunoglobulin M autoantibodies to proteins mimicking and not mimicking Epstein-Barr virus nuclear antigen-1.

Authors:  J H Vaughan; J R Valbracht; M D Nguyen; H H Handley; R S Smith; K Patrick; G H Rhodes
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

Review 4.  The Epstein-Barr virus in autoimmunity.

Authors:  J H Vaughan
Journal:  Springer Semin Immunopathol       Date:  1995

5.  Cross-reactivity of Epstein-Barr virus-specific immunoglobulin M antibodies with cytomegalovirus antigens containing glycine homopolymers.

Authors:  D Lang; R Vornhagen; M Rothe; W Hinderer; H H Sonneborn; B Plachter
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

6.  False positive immunoglobulin m antibody to cytomegalovirus in child with infectious mononucleosis caused by epstein-barr virus infection.

Authors:  Jee Min Park; Jae Il Shin; Jae Seung Lee; Young Ho Jang; Sung Hun Kim; Kang Hyuk Lee; Chang Hoon Lee
Journal:  Yonsei Med J       Date:  2009-10-21       Impact factor: 2.759

7.  Epstein-Barr virus-induced autoimmune responses. II. Immunoglobulin G autoantibodies to mimicking and nonmimicking epitopes. Presence in autoimmune disease.

Authors:  J H Vaughan; M D Nguyen; J R Valbracht; K Patrick; G H Rhodes
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

8.  Rapid identification of novel immunodominant proteins and characterization of a specific linear epitope of Campylobacter jejuni.

Authors:  Sebastian Hoppe; Frank F Bier; Markus von Nickisch-Rosenegk; Markus V Nickisch-Rosenegk
Journal:  PLoS One       Date:  2013-05-29       Impact factor: 3.240

9.  Whole CMV proteome pattern recognition analysis after HSCT identifies unique epitope targets associated with the CMV status.

Authors:  Lena Pérez-Bercoff; Davide Valentini; Simani Gaseitsiwe; Shahnaz Mahdavifar; Mike Schutkowski; Thomas Poiret; Åsa Pérez-Bercoff; Per Ljungman; Markus J Maeurer
Journal:  PLoS One       Date:  2014-04-16       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.